Form 144 Hims & Hers Health, Inc. Filed by: Boughton Soleil
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Hims and Hers (HIMS) PT Lowered to $18 at Jefferies
August 7, 2024 10:16 AM EDTJefferies analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $18.00 (from $23.00) while maintaining a Hold rating.
The analyst comments "We are updating our model following 2Q results and management's initial commentary on GLP-1s. We are raising our revenue... More
Hims and Hers (HIMS) PT Raised to $23 at Deutsche Bank
August 6, 2024 4:22 PM EDTDeutsche Bank analyst George Hill raised the price target on Hims and Hers (NYSE: HIMS) to $23.00 (from $16.00) while maintaining a Hold rating.
The analyst comments "Positioned to Grow Specialty Platform: HIMS reported a Q2 beat on a broad basis AMC on Monday where the GLP-1 opportunity in the near term was the overwhelming focus of the earnings call. Since the company... More
